Ivana M. Djuretic

机构：Atara Biotherapeutics (United States) · ORCID：0009-0007-1094-3247

发表论文 147 篇 · 总被引 3361 次 · h-index 19

代表论文

• Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy (2024 · Nature · 被引 103)
• Selective Support of CAR-T Cell Therapies By Cis-Targeted IL-2 Enhances Anti-Tumor Activity and Obviates the Need for Lymphodepletion in Non-Human Primates (2024 · Blood · 被引 3)
• Reinvigoration of translational activity in dysfunctional T cells initiates the early intratumoral response to PD-1 blockade (2025 · bioRxiv (Cold Spring Harbor Laboratory) · 被引 2)
• Phase 1 clinical trial investigating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of AB821 in adult patients with locally advanced or metastatic melanoma and other solid tumor malignancies (NCT 07027488). (2026 · Journal of Clinical Oncology · 被引 1)
• Phase 1A/B study of AB248, a CD8+ selective IL-2 mutein fusion protein, alone or in combination with pembrolizumab, in patients with advanced solid tumor malignancies. (2026 · Journal of Clinical Oncology · 被引 1)
• Personalized Neoantigen Vaccines Synergize with Immune Checkpoint Therapy and CD8-Targeted Cytokines to Control B-Cell Lymphoma (2026 · bioRxiv (Cold Spring Harbor Laboratory))